Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPERA-RADIO: Adjuvant Durvalumab for Esophageal Cancer
NCT05667298Phase 1Active, not recruiting
- Sponsor
- University of Manitoba
- Start
- Mar 2023
- Primary completion
- Jun 2025
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
Phase 1, open-label trial of durvalumab in esophageal cancer (2 arms), sponsored by University of Manitoba. Primary endpoints: Feasibility of enrolling 10 patients at 1.5 years and Proportion of patients developing Grade 3 or above adverse events at 1.5 years. Started Mar 2023; status: active, not recruiting.
02
Drugs
durvalumab
03
Conditions
esophageal cancer
Beyond the preview
Go deeper on NCT05667298.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05667298.